News
Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab’s antibody discovery platform. Cambridge, UK, 9 January 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a collaboration with Lilly to discover novel […]
Cambridge, UK, 12 September 2024 – Alchemab Therapeutics (Alchemab), a pharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that Jane Osbourn, OBE, FMEDSCI, PhD, Alchemab’s Chief Scientific Officer (CSO), has succeeded Young Kwon, PhD as Chief Executive Officer (CEO) and member of the Board. As Co-Founder and […]
Cambridge, UK, 06 June 2024 – Alchemab Therapeutics (Alchemab), an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announces that it has been awarded a grant of US$595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease program. The grant will fund research performed […]
Publication in Nature Immunology outlining the contribution of B cells to anticancer immunosurveillance highlights Alchemab’s capabilities and potential to develop new cancer therapies Cambridge, UK, 14 May 2024 – Alchemab Therapeutics (Alchemab), an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announces the publication of a peer reviewed article titled […]
Nature Immunology - Published in the journal Nature Immunology, this paper provides an important perspective on the role that B cells play in the immune response to cancer that will help the development of improved therapies to treat these diseases.
Alzforum - Alchemab was delighted to see this article in Alzforum highlighting Alchemab’s unique platform and preclinical Alzheimers candidate ATLX-1088 targeting CD33. This article explores data that Ralph Minter, our Senior Vice President of Research, presented at AD/PD –Advances in Science & Therapy 2024 International Conference on Alzheimer’s and Parkinson’s Diseases.
AD/PD 2024 - Ralph Minter, Ph.D. presented “Resilience-Associated CD33 Antibody ATLX-1088, A Potent Stimulator of Microglial Phagocytosis” at AD/PD 2024, the International Conference on Alzheimer’s and Parkinson’s Diseases held 6th March 2024.
Machine Learning for Structural Biology Workshop, NeurIPS 2023 - Alchemab publication and NeurIPS Machine Learning in Structural Biology workshop.
Cold Spring Harbour Perspectives in Biology, November 2023 -
The Society of Neuroscience Annual Meeting 2023 - Michelle Sidor and Iosif Pediaditakis presented the following posters: ‘Human-derived CD33 antibody ATLX-1088, a potent stimulator of microglial pharmacology’ and ‘Netrin-1 and neurodegenerative diseases: Unraveling Therapeutic Avenues’.
Pharmaphorum Podcast. - Listen to our CEO, Young Kwon discuss Alchemab’s innovative platform and its novel approach to drug discovery on the pharmaphorum podcast. Learn More.
Cambridge, UK, September 5, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that Young Kwon, PhD, Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 2023 Healthcare Conference on 7 September 2023 at 4:30 p.m. ET. Please click here to […]
Optimum Perspectives Podcast - Our CEO Young Kwon was delighted to speak with Richard Staines of the Optimum Perspectives Podcast on how Alchemab is revolutionizing antibody drug discovery with a novel alternative to the classic “choose a target” approach.
Drug Target Review - Alchemab CEO Young Kwon and Taylor Mixides from Drug Target Review discuss how Alchemab’s research has significant potential to transform the landscape of neurodegenerative disease research and improve the lives of those affected by these challenging conditions.
Drug Target Review 2023 - Alchemab was delighted to be featured in Drug Target Review in a profile by Izzy Wood. In the article, Izzy and Olivia Cavlan, our Chief Corporate Development and Strategy Officer, discuss the untapped potential of AI in drug target discovery and how Alchemab’s platform aims to identify common antibodies in resilient individuals and uncover the […]
Antibody Industrial Symposium 2023 - Alchemab’s Sandrine Legg, Director of Phenotypic Screening presented data on a potential first-in-class disease-modifying therapeutic for Alzheimer’s disease at the Antibody Industrial Symposium in Tours, France on 22 June 2023.
Cambridge, UK, June 22, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium in Tours, France, 22-23 June 2023. ATLX-1088 is a potential first-in-class human antibody targeting CD33, a […]
CHDI Huntington’s Disease Therapeutics Conference - Alchemab’s Donna Finch, Head of Translational and Clinical Science, presented data on a potential first-in-class disease modifying therapeutic for Huntington’s Disease at the annual CHDI Huntington’s Disease Therapeutics Conference in Dubrovnik, Croatia, on the 26 April 2023.
Alchemab’s Donna Finch, Head of Translational and Clinical Science, presented data on a potential first-in-class disease modifying therapeutic for Huntington’s Disease at the annual CHDI Huntington’s Disease Therapeutics Conference in Dubrovnik, Croatia, on the 26 April 2023. Our innovative, target agnostic discovery platform, which combines data analysis of hundreds of millions of individual antibodies with […]
Cambridge, UK, April 25, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it will present data on a potential first-in-class disease modifying therapeutic for Huntington’s Disease at the annual CHDI Huntington’s Disease Therapeutics Conferencein Dubrovnik, Croatia, 24-27 April 2023. Alchemab’s innovative, target agnostic discovery platform, which combines data analysis of hundreds of millions of individual antibodies with classical laboratory-based drug discovery techniques, has discovered antibodies which bind to multiple extracellular forms […]
Company plans to triage a panel of antibodies towards first in human studies Cambridge, UK. December 16 2022 – Alchemab Therapeutics, a biotechnology company unlocking new therapies from within the immune system, today announced that it has been awarded a grant of £1.7 million (US$2 million) from Innovate UK’s Biomedical Catalyst (‘BMC’) 2022 funding competition, […]
The Chain Podcast - Our Co-Founder and CSO Jane Osbourn was delighted to speak with her longtime friend Ahuva Nissim, antibody and therapeutic engineering professor at William Harvey Research Institute, Queen Mary University of London, about the career path that took her from studying molecular biology and building human phage libraries to developing therapeutics with convergent protective antibodies. She […]
Nature Biotechnology - Thank you to Nature Biotechnology for including Alchemab in NBT’s Class of 2021 biotechs! Their article features an interview with Jane Osbourn, Olivia Cavlan and Young Kwon alongside some very exciting startups.
In Vivo - Many thanks to Chloe Kent at In Vivo for her great interview with our CEO Young Kwon. In her story, titled Alchemab Is Bringing A New Meaning To Patient Centered Care, Chloe explores how the first step in our drug discovery journey starts with individual patients. As we target diseases across neurology and oncology through […]
Nature Biotechnology 2022 - Alchemab was delighted to be featured in Nature Biotechnology in a profile by Michael Eisenstein. In the article he speaks with Young Kwon, our CEO, and Jane Osbourn, our founder and CSO, about Alchemab’s revolutionary approach of looking for protective antibodies in ‘resilient’ people which may provide a new approach for discovering drug targets: “Our […]
Waltham, Massachusetts and Cambridge, UK May 26, 2022 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, announced that Young T. Kwon, PhD, Alchemab’s Chief Financial and Operating Officer, has succeeded Douglas A. Treco, PhD as Chief Executive Officer and member of […]
Boston, Massachusetts and Cambridge, UK May 19, 2022 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, today announced the publication of research demonstrating the potential of AntiBERTa (Antibody-specific Bi-directional Encoder Representation and Transformers), a transformer neural network that reads the components […]
Genomics England Research Summit 2022 - Learn more about B cell immune repertoires from Jane Osbourn, Alchemab CSO & co-founder, presenting at the Genomics England Research Summit
Boston, Massachusetts and Cambridge, UK March 22, 2022 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, has been selected by NVIDIA to harness the power of the UK’s most powerful supercomputer, Cambridge-1. Alchemab will use the NVIDIA DGX SuperPOD supercomputing cluster, […]
Boston, Massachusetts and Cambridge, UK March 7, 2022 – Alchemab Therapeutics – a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, has announced an extension of its collaboration with Medicines Discovery Catapult (MDC), a national facility enabling the UK’s community to accelerate innovative drug discovery. The collaboration […]
Boston, Massachusetts and Cambridge, UK November 15, 2021 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, today announced the appointment of Young T. Kwon, PhD as Chief Financial and Operating Officer. “We are thrilled to welcome Young to the Alchemab management team and […]
Industry Veteran Brings Experience and Proven Track Record of Success Plans for Management Team Expansion and Global Reach Through Newly Established U.S. Office Cambridge, UK and Boston, Massachusetts, June 22, 2021 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, today announced the appointment of […]
Frontiers in Immunology - Passive immunization using monoclonal antibodies will play a vital role in the fight against COVID-19. The recent emergence of viral variants with reduced sensitivity to some current antibodies and vaccines highlights the importance of broad cross-reactivity.
OBN Awards - We are delighted to announce the winners of the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.
Cambridge, UK, 5 May 2021 – Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has formed a collaboration with AstraZeneca to accelerate prostate cancer research.
Cambridge, UK, 15 April 2021 – Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.
London, UK, 16 March 2021 – Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support the development of a novel disease-modifying antibody therapy for Huntington’s disease (HD). The grant will support Alchemab in its pioneering collaboration with Medicines Discovery Catapult.
Frontiers in Immunology - Deep sequencing of B cell receptor (BCR) heavy chains from a cohort of 31 COVID-19 patients from the UK reveals a stereotypical naive immune response to SARS-CoV-2 which is consistent across patients. Clonal expansion of the B cell population is also observed and may be the result of memory bystander effects.
Business Weekly - The operating landscape has changed remarkably for many life science and technology businesses in the Cambridge Cluster since the March 23 lockdown and subsequent restrictions affecting lifestyle and working practices.
Business Weekly - The UK BIA Antibody Taskforce, a UK consortium developing antibodies for treating COVID-19, has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody cocktail.
Bio Industry - The UK BIA Antibody Taskforce, a leading UK consortium developing antibodies for treating COVID-19 has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody “cocktail”. The Taskforce developed an accelerated and rigorous multifaceted approach to create a pool of over 600 novel […]
Bio Industry - Alchemab, a UK biotech company focused on harnessing the power of adaptive immune systems to cure disease, announced a strategic partnership with the Alberta Machine Intelligence Institute (Amii) to accelerate its adoption of artificial intelligence.
Three companies at Oxford’s BioEscalator are developing new detection methods and have discovered potential therapeutics in the fight against COVID-19. Even before the lockdown began, Nucleome Therapeutics, Alchemab Therapeutics and Hutano Diagnostics all quickly redirected their scientific expertise and business plans. These rapid innovations were achieved through collaborations with nearby experts, highlighting the importance of […]
Business Weekly - Two Cambridge companies fly the flag for the UK cluster in the first global cohort of Illumina’s genomics accelerator. Alchemab Therapeutics and Tailor Bio are among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK.
Illumina, Inc. has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups.
Business Weekly - A novel Cambridge UK life science startup – Alchemab Therapeutics – looks set for global glory by identifying and harnessing the power of naturally protective antibodies to combat a broad range of hard-to-treat diseases.
20 May 2020 – Alchemab’s publication illustrating progress in understanding patients’ immune responses to COVID19 which will help inform vaccination and antibody therapeutics.
BioCentury - Crisis is the mother of invention and COVID-19 is no exception. But amid all the gloom are signs of a nascent revolution in how we create and develop new drugs, vaccines and diagnostics. The U.K. life sciences industry is rising to the challenge with a mix of collaboration, speed, creativity and resource commitment, to capitalize […]